Anti-tumor activity of tumor necrosis factor alone and combination with VP-16 on renal cell carcinoma in a nude mice xenograft model / 대한비뇨기과학회지
Korean Journal of Urology
;
: 954-960, 1992.
Artigo
em Coreano
| WPRIM
| ID: wpr-123243
ABSTRACT
Investigations of the anti-tumor activity of recombinant mouse TNF and etoposide(VP-16) in a nude mouse subcutaneous implantation xenograft model utilizing the CURC-1 human renal cell carcinoma cell line were performed. Recombinant mouse tumor necrosis factor-alpha(rTNF-alpha) and VP-16. both well known cytotoxic and cytostatic anticancer agents were evaluated singly and in combination against subcutaneously growing CURC-1. The results were as follows 1. In the absence of treatment(Group I). subcutaneously growing CURC-1 tumor nodules demonstrated continued rapid growth. 2. Administration of rTNF(Group II) induced significant tumor regression in the subcutaneous nodules. 3. Administration of rTNF and Etoposide(Group III) demonstrated significant tumor growth inhibition. On histopathological findings, Group I (control) shows rare leukocyte infiltration and no tumor necrosis. In contrast, Group II shows tumor necrosis and more leukocyte infiltration than Group I . Group III demonstrates tumor necrosis. tumor cell degeneration and more leukocyte infiltration than Group II. These results suggest that TNF have antineoplastic effect against subcutaneous human renal cell carcinoma nodule but the synergistic effect of TNF with VP-l6 is uncertain.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Robenidina
/
Carcinoma de Células Renais
/
Linhagem Celular
/
Fator de Necrose Tumoral alfa
/
Etoposídeo
/
Xenoenxertos
/
Leucócitos
/
Camundongos Nus
/
Necrose
/
Antineoplásicos
Tipo de estudo:
Estudo prognóstico
Limite:
Animais
/
Humanos
Idioma:
Coreano
Revista:
Korean Journal of Urology
Ano de publicação:
1992
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS